SG11201608403TA - Epigenetic modification of mammalian genomes using targeted endonucleases - Google Patents

Epigenetic modification of mammalian genomes using targeted endonucleases

Info

Publication number
SG11201608403TA
SG11201608403TA SG11201608403TA SG11201608403TA SG11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA
Authority
SG
Singapore
Prior art keywords
epigenetic modification
mammalian genomes
targeted endonucleases
endonucleases
targeted
Prior art date
Application number
SG11201608403TA
Other languages
English (en)
Inventor
Gregory D Davis
Qiaohua Kang
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of SG11201608403TA publication Critical patent/SG11201608403TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
SG11201608403TA 2014-04-28 2015-04-24 Epigenetic modification of mammalian genomes using targeted endonucleases SG11201608403TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461985205P 2014-04-28 2014-04-28
PCT/US2015/027541 WO2015167959A1 (en) 2014-04-28 2015-04-24 Epigenetic modification of mammalian genomes using targeted endonucleases

Publications (1)

Publication Number Publication Date
SG11201608403TA true SG11201608403TA (en) 2016-11-29

Family

ID=54359184

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608403TA SG11201608403TA (en) 2014-04-28 2015-04-24 Epigenetic modification of mammalian genomes using targeted endonucleases

Country Status (6)

Country Link
US (2) US20170051354A1 (zh)
EP (1) EP3137633A4 (zh)
JP (1) JP2017517250A (zh)
CN (1) CN106460050A (zh)
SG (1) SG11201608403TA (zh)
WO (1) WO2015167959A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
EP2791361B9 (en) 2011-12-13 2018-07-11 Oslo Universitetssykehus HF Methods and kits for detection of methylation status
CN104955960A (zh) 2012-11-30 2015-09-30 剑桥表现遗传学有限公司 用于修饰的核苷酸的氧化剂
US11459573B2 (en) 2015-09-30 2022-10-04 Trustees Of Boston University Deadman and passcode microbial kill switches
JP2019501657A (ja) * 2016-01-14 2019-01-24 メンフィス ミーツ インコーポレイテッド 生体外培養工程中の体細胞の複製能拡張法
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
EP3612623A4 (en) 2017-05-06 2021-06-23 Memphis Meats, Inc. COMPOSITIONS AND METHODS FOR INCREASING THE CULTURE DENSITY OF A CELLULAR BIOMASS IN A CULTURE INFRASTRUCTURE
KR20180136905A (ko) * 2017-06-15 2018-12-26 주식회사 툴젠 반복 확장 돌연변이에 대한 게놈 편집 시스템
US11479792B2 (en) 2017-07-13 2022-10-25 Upside Foods, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
US20220112509A1 (en) * 2020-02-26 2022-04-14 Imra Japan Kabushikikaisha Gene knock-in method, gene knock-in cell fabrication method, gene knock-in cell, malignant transformation risk evaluation method, cancer cell production method, and kit for use in these
KR20230083269A (ko) 2020-07-30 2023-06-09 캠브리지 에피제네틱스 리미티드 핵산 분석을 위한 조성물 및 방법
CN112430662B (zh) * 2020-12-11 2022-02-22 中国医学科学院肿瘤医院 一种用于预测肺鳞癌预后风险的试剂盒及其应用
CA3233868A1 (en) * 2021-10-08 2023-04-13 Eddie Adams Metaepigenomics-based disease diagnostics
CN114574493A (zh) * 2022-04-02 2022-06-03 中国科学院遗传与发育生物学研究所 一种编辑绵羊SOCS2基因的sgRNA组合、扩增用引物和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152413A (en) * 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
CA2110899C (en) * 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
GB9818591D0 (en) * 1998-08-27 1998-10-21 Danbiosyst Uk Pharmaceutical composition
US20050282157A1 (en) * 2000-04-06 2005-12-22 Alexander Olek Diagnosis of diseases associated with dna replication
US20090269736A1 (en) * 2002-10-01 2009-10-29 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
US20070134796A1 (en) * 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
WO2011026111A1 (en) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
WO2011082436A1 (en) * 2010-01-04 2011-07-07 Lineagen, Inc. Dna methylation biomarkers of lung function
WO2011100058A1 (en) * 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US8902648B2 (en) * 2011-07-26 2014-12-02 Micron Technology, Inc. Dynamic program window determination in a memory device
EP2830599B1 (en) * 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
EP3839050A3 (en) * 2012-04-18 2021-09-29 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting

Also Published As

Publication number Publication date
EP3137633A4 (en) 2017-11-29
JP2017517250A (ja) 2017-06-29
EP3137633A1 (en) 2017-03-08
US20170051354A1 (en) 2017-02-23
US20190271041A1 (en) 2019-09-05
WO2015167959A1 (en) 2015-11-05
CN106460050A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
SG11201608403TA (en) Epigenetic modification of mammalian genomes using targeted endonucleases
IL247973A0 (en) Methods for purifying messenger RNA
SG11201609265RA (en) Characterizing states of subject
AP2016009496A0 (en) Substituted spirocydic inhibitors of autotaxin
IL251988A0 (en) Compounds acting on glycans and methods of using them
HRP20190432T1 (hr) Spojevi pladienolid piridina i postupci uporabe
PT3201361T (pt) Métodos de quantificação de adn acelular
RS60718B1 (sr) Jedinjenja i načini upotrebe
GB201415761D0 (en) Methods for detection of Nucleotide modification
PL3237356T3 (pl) Zastosowanie wyrobów ogniotrwałych
ZA201606450B (en) Compounds and their methods of use
GB201402169D0 (en) Viral inhibitors
HK1231403A1 (zh) 抑制β 表達的核酸
SG11201702844VA (en) Photobioreactor
SG11201607445QA (en) Methods of modulating wars2
TWM490344U (en) Improved structure of grasping claws
GB201403697D0 (en) Compounds and methods of use
GB201508443D0 (en) Methods of identifying USP-binding compounds
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny
GB201417348D0 (en) Prodrugs of lxazomib
GB201417347D0 (en) Prodrugs of delanzomib
GB201414314D0 (en) Manufacture of graphene
HUP1400294A2 (hu) Clopidogrel új alkalmazása